CD79A and COVID-19: In support of this hypothesis, Zang et.al demonstrated the presence of antiphospholipid antibodies targeting phospholipid proteins (Anticardiolipin IgA, anti-β2 glycoprotein I IgA and IgG), characteristic of antiphospholipid syndrome (APS), in three patients with admitted to the ICU with COVID-19 and coagulopathy [98].